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Abstract
Background: Metabolic syndrome (MS) is prevalent in chronic kidney disease (CKD). Klotho, a protein linked to
aging, is closely associated with CKD. Each component of MS and klotho has an association. However, little is
known about the association between klotho and MS per se. We investigated the association between serum
klotho levels and MS using baseline cross-sectional data obtained from a large Korean CKD cohort.
Methods: Of the 2238 subjects recruited in the KoreaN Cohort Study for Outcome in Patients With Chronic Kidney
Disease (KNOW-CKD) between 2011 and 2016, 484 patients with missing data on serum klotho and extreme klotho
values (values lower than the detectable range or > 6000 pg/mL) or with autosomal dominant polycystic kidney
disease patients were excluded. The data of the remaining 1754 subjects were included in the present study. MS
was defined using the revised National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP) III criteria.
Serum klotho levels were measured using an enzyme-linked immunosorbent assay.
Results: Mean patient age was 54.9 ± 12.1 years and 1110 (63.3%) were male. The prevalence of MS among all study
subjects was 63.7% (n = 1118). The median serum klotho level was 527 pg/mL (interquartile range [IQR]: 418–656 pg/mL).
Serum klotho level was significantly lower in MS patients than patients without MS (Median [IQR]; 521 pg/mL [413, 651]
vs. 541 pg/mL [427, 676], respectively; P = 0.012). After adjusting for age, sex, estimated glomerular filtration rate, and overt
proteinuria, serum klotho was independently associated with MS (adjusted odds ratio [OR], 0.44; 95% confidence interval,
0.23–0.82; P = 0.010). Furthermore, the adjusted OR for MS was found to be significantly increased at serum klotho levels
of < 518 pg/mL (receiver operating characteristic curve cut-off value).
Conclusions: Serum klotho was inversely associated with the presence of MS in patients with CKD.
Trial registration: This trial was registered on ClinicalTrials.gov on 26 June 2012 (https://clinicaltrials.gov;NCT01630486).
Keywords: Chronic kidney disease, Klotho, Metabolic syndrome
Background
Metabolic syndrome (MS) is a cluster of risk factors
for diabetes and cardiovascular (CV) disease and is
characterized by hypertension, hyperglycemia,
hypertriglyceridemia, decreased high-density lipopro-
tein (HDL) cholesterol, and abdominal obesity [1, 2].
Furthermore, MS is common in chronic kidney
disease (CKD) patients [3]. Previous studies showed
that MS was independently associated with an in-
creased risk for CKD and vice versa [4, 5].
Klotho, a protein linked to aging, is closely associ-
ated with CKD. In a previous study, klotho knock-out
mice exhibited similarities with CKD patients, such
as, hyperphosphatemia, ectopic soft tissue calcifica-
tion, and arteriosclerosis [6], which suggested CKD
might result from a state of klotho deficiency. Thus,
in addition to serving as a biomarker for CKD, klotho
deficiency is also viewed as a pathogenetic indicator
of renal and extra-renal complications in CKD [7].
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Recent reports indicated klotho is associated with
each component of MS. Arking et al. [8] showed that
a functional variant of the Klotho gene was associated
with increased systolic blood pressure and decreased
HDL-cholesterol levels in 525 Jewish subjects. In ex-
perimental studies, klotho has been shown to amelior-
ate vascular endothelial dysfunction, to increase nitric
oxide production, and to reduce elevated blood pres-
sure in an animal models of MS [9, 10]. Klotho poly-
morphism was significantly associated with glucose
metabolism in apparently healthy Korean females
[11]. In addition, genetic variants of Klotho have been
associated with insulin resistance and hypertriglyc-
eridemia [12]. Accordingly, it was suggested in all of
these studies that klotho be considered a candidate
molecule in MS. However, little is known about the
association between klotho and MS per se in CKD
patients. In the present study, we investigated the
metabolic profile characteristics of Korean CKD pa-
tients and evaluated the association between serum
klotho and MS using baseline cross-sectional data ob-
tained from a large Korean CKD cohort.
Methods
Study population
We conducted a cross-sectional analysis of clinical profiles
obtained at enrollment for the KoreaN Cohort Study for
Outcome in Patients With Chronic Kidney Disease
(KNOW-CKD) study. KNOW-CKD is a nationwide pro-
spective cohort study, including predialysis subjects with
CKD from stage 1 to 5, aged between 20 and 75 years and
recruited from nine clinical centers of major
university-affiliated Korean hospitals. Details of the ration-
ale and study design of the KNOW-CKD have been de-
scribed elsewhere [13]. Of 2238 CKD patients recruited
between June 2011 and January 2016, 484 were excluded
for the following reasons: 125 for missing serum klotho
data; 9 for a serum klotho level lower than the detectable
range; 3 for an extremely higher klotho level (> 6000 pg/
mL); and 347 for autosomal dominant polycystic kidney
disease patients because large cystic masses in their kidneys
and liver can cause an overestimation of abdominal obesity.
Extreme klotho values were not influence value by Cook’s
distance analysis. Finally, 1754 CKD patients were included
in the cross-sectional analysis. Klotho expression is known
to decline in cases of acute kidney injury, regardless of
whether it is caused by ischemia, infection, a toxin, or ur-
eteral obstruction [14–16]. However, in the present study,
we did not enroll patients with acute illness at the time of
initial enrollment. Therefore, it is unlikely that initial klotho
levels were influenced by acute illness. The study protocol
was approved by the ethical committees of participating
clinical centers, that is, by the Institutional Review Boards
of Seoul National University Hospital (1104–089-359),
Seoul National University Bundang Hospital (B-1106/129–
008), Yonsei University Severance Hospital (4–2011-0163),
Kangbuk Samsung Medical Center (2011–01-076),
Seoul St. Mary’s Hospital (KC11OIMI0441), Gil Hospital
(GIRBA2553), Eulji General Hospital (201105–01),
Chonnam National University Hospital (CNUH-2011-092),
and Pusan Paik Hospital (11–091) in 2011. All study sub-
jects provided written informed consent. This study was
performed in accordance with the principles of the Declar-
ation of Helsinki.
Clinical data collection and laboratory analyses
Laboratory values and demographic characteristics at
enrollment were extracted from an electronic case-
reporting form (http://www.phactax.org) developed by
the assistance of the Division of Data Management at
Seoul National University Medical Research Collabor-
ating Center. Waist circumferences were measured
midway between the lower part of the lowest rib and
the upper iliac crest using a standardized protocol at
clinics, as recommended by the World Health
Organization (WHO) [17]. Brachial systolic blood
pressure (SBP) and diastolic blood pressure (DBP)
were obtained by averaging two measurements (sepa-
rated by a minimum rest of 5 min in the sitting pos-
ition) obtained using a calibrated oscillometric device
(BP-203RV III; Omron Co., Kyoto, Japan). Serum cre-
atinine levels were measured by an isotope dilution
mass spectrometry (IDMS)-traceable method [18] at a
central laboratory. Estimated glomerular filtration rate
(eGFR) was calculated using the Chronic Kidney Dis-
ease Epidemiology Collaboration (CKD-EPI) creatinine
equation [19]. Fasting blood glucose and triglyceride
levels were measured in the hospital laboratories of par-
ticipating center according to a standardized protocol.
Overt proteinuria was defined as a 24-h urine protein
result of > 500 mg/day. Serum α-klotho level was mea-
sured using an enzyme linked immunosorbent assay
(ELISA) kit (Immuno-Biological Laboratories Co.,
Gunma, Japan) according to the manufacturer’s instruc-
tions [20]. The intra- and inter-assay coefficients of
variation of this kit were 2.7–3.5% (klotho levels
186.64–2968.78 pg/mL) and 2.9–11.4% (klotho levels
165.47–2903.01 pg/mL), respectively. The data for
intra- and inter-assay coefficients of variations were
validated in our central laboratory by measurements of
a serum control in 20 repeats on each ELISA plate. The
intra- and inter-assay coefficients of variations were
0.57–1.78% and 3.01–6.12% (klotho levels 120.30–
4468.50 pg/mL), respectively. The standard curve was
shown to be linear up to 4000 pg/mL. C-terminal
FGF23 was measured using a second generation human
FGF23 ELISA kit (Immutopics, San Clemente, Califor-
nia, USA) according to the manufacturer’s instructions.
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Age (years) 54.9 ± 12.1 52.3 ± 12.8 56.3 ± 11.4 < 0.001
Sex, male, n (%) 1110 (63.3) 387 (60.8) 723 (64.7) 0.111
SBP (mmHg) 128.5 ± 17.0 124.9 ± 16.4 130.6 ± 17.0 < 0.001
DBP (mmHg) 76.0 ± 11.2 75.5 ± 10.9 76.5 ± 11.4 0.059
BMI (kg/m2) 24.7 ± 3.4 22.9 ± 2.9 25.8 ± 3.2 < 0.001
Waist circumference (cm) 88.1 ± 9.8 81.4 ± 8.4 91.7 ± 8.5 < 0.001
DM, n (%) 700 (39.9) 110 (17.3) 590 (52.8) < 0.001
Hypertension, n (%) 1719 (98.0) 606 (95.3) 1113 (99.6) < 0.001
Preexisting CV disease, n (%) 298 (17.0) 72 (11.3) 226 (20.2) < 0.001
CAD, n (%) 110 (6.3) 21 (3.3) 89 (8.0) < 0.001
PVD, n (%) 76 (4.3) 22 (3.5) 54 (4.8) 0.175
Cerebrovascular disease, n (%) 110 (6.3) 24 (3.8) 86 (7.7) 0.001
HF, n (%) 28 (1.6) 9 (1.4) 19 (1.7) 0.648
Arrhythmia, n (%) 52 (3.0) 19 (3.0) 33 (3.0) 0.966
Cause of CKD, n (%) < 0.001
GN, n (%) 746 (42.5) 387 (60.8) 359 (32.1)
Diabetic nephropathy, n (%) 491 (28.0) 72 (11.3) 419 (37.5)
Hypertension, n (%) 389 (22.2) 142 (22.3) 247 (22.1)
Others, n (%) 128 (7.3) 35 (5.5) 93 (8.3)
Laboratory findings
eGFR (mL/min/1.73m2) 49.1 ± 28.6 53.1 ± 29.6 46.8 ± 27.9 < 0.001
Hemoglobin (g/dL) 12.7 ± 2.1 12.8 ± 2.0 12.7 ± 2.1 0.798
Albumin (g/dL) 4.1 ± 0.4 4.1 ± 0.4 4.1 ± 0.5 0.357
Uric acid (mg/dL) 7.2 ± 1.9 7.1 ± 1.9 7.3 ± 1.9 0.025
Creatinine (mg/dL) 1.9 ± 1.2 1.8 ± 1.1 2.0 ± 1.2 0.002
hsCRP, median, (IQR) (mg/dL) 0.07 (0.03, 0.17) 0.04 (0.02, 0.11) 0.08 (0.03, 0.21) 0.005
Fasting blood sugar (mg/dL) 113.9 ± 42.7 100.4 ± 28.5 121.5 ± 47.2 < 0.001
Total cholesterol (mg/dL) 173.4 ± 40.4 173.5 ± 36.2 173.3 ± 42.5 0.917
Triglyceride (mg/dL) 164.1 ± 103.1 106.3 ± 52.0 196.0 ± 110.2 < 0.001
LDL cholesterol (mg/dL) 95.0 ± 32.7 96.5 ± 30.1 95.7 ± 34.1 0.609
HDL cholesterol (mg/dL) 48.2 ± 15.5 56.5 ± 15.0 43.7 ± 13.8 < 0.001
Overt proteinuriaa, n (%) 942 (61.0) 319 (58.3) 623 (62.5) 0.108
Medication, n (%)
ACEi or ARB, n (%) 1521 (86.9) 526 (83.0) 995 (89.1) < 0.001
Diuretics, n (%) 443 (25.3) 99 (15.6) 344 (25.3) < 0.001
Statin, n (%) 998 (56.9) 323 (50.8) 675 (60.4) < 0.001
Ca-based P binders, n (%) 161 (9.2) 67 (10.5) 94 (8.4) 0.179
a24-h urine protein > 500 mg/day
MS metabolic syndrome, SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, DM diabetes mellitus, CV cardiovascular, CAD coronary
artery disease, HF heart failure, PVD peripheral vascular disease, CKD chronic kidney disease, GN glomerulonephritis, eGFR estimated glomerular filtration rate by
CKD-EPI creatinine equation, hsCRP high sensitivity C-reactive protein, IQR interquartile range, LDL low-density lipoprotein, HDL high-density lipoprotein, ACEi
angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, Ca calcium, P phosphorus
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The intra- and inter-assay coefficients of variation as
informed by the manufacturer were 1.4–2.4% (FGF23
levels 33.7–302 RU/mL) and 2.4–4.7% (FGF23 levels
33.6–293 RU/mL), respectively.
Definition of metabolic syndrome
MS was defined using the modified National Choles-
terol Education Program Adult Treatment Panel
(NCEP-ATP) III criteria according to American Heart
Association/National Heart, Lung, and Blood Institute
Scientific Statement, which adopted the Asian-Pacific
waist circumference threshold by WHO. Subjects with
three or more of the following 5 metabolic components
were defined as having MS [2, 21]: 1) history of hyperten-
sion, elevated blood pressure (systolic blood pressure ≥
130mmHg, or diastolic blood pressure ≥ 85mmHg), or
taking anti-hypertensive medication; 2) history of diabetes
mellitus, elevated fasting plasma glucose (≥100mg/dL), or
the use of anti-diabetes medication; 3) elevated triglycer-
ides (≥150mg/dL), or on drug treatment for elevated tri-
glycerides; 4) reduced HDL cholesterol (< 40mg/dL for
men and < 50mg/dL for women), or on drug treatment
for reduced HDL cholesterol; and 5) elevated waist cir-
cumference (≥90 cm for men and ≥ 80 cm for women) ac-
cording to the Asia-Pacific criteria [21, 22].
Statistical analysis
Categorical variables were evaluated using the
Chi-square test or Fisher’s exact test and presented as
frequencies and percentages. Continuous variables
were analyzed with independent sample t-tests or the
Mann-Whitney U test. Results are presented as the
mean ± standard deviation (SD) for normally distrib-
uted variables and the median (interquartile range
[IQR]) for variables with skewed distributions. Log
transformation was used to normalize klotho variabil-
ity. We performed binominal logistic regression model
analysis with adjustments (the Enter method), including
variables that were significant in a univariate analysis or
other clinically relevant variables to investigate the inde-
pendent risk factors related to MS. To explore the associ-
ation between MS and eGFR, or between MS and serum
klotho considering the possible non-linearity, we adopted
3-knots restricted cubic splines with 95% confidence inter-
val (CI) which described odds ratios (ORs) of MS accord-
ing to the eGFR or klotho level. Knots were chosen using
SAS LGTPHCURV9 Macro by Li et al. at the eGFR of
13.4, 42.7, and 106ml/min/1.73m2; 257, 526, and 946 pg/
mL for klotho, respectively. An eGFR of 60ml/min/
1.73m2, as a reference value of decreased renal function,
and a serum klotho of 518 pg/mL (ROC [receiver operat-
ing characteristic] curve cut-off value) were taken as the
reference point (OR = 1.00). The final model was ad-
justed for confounders. In subgroup analyses using an
adjusted binominal logistic regression model (adjusted
for age, sex, eGFR, overt proteinuria), we categorized
patients according to age (aged < 50 vs. ≥50 years),
sex, and CKD stages. P-values of < 0.05 were consid-
ered statistically significant. The SPSS statistical soft-
ware (SPSS version 18.0, Chicago, IL, USA) and SAS
Fig. 1 Prevalence of the metabolic syndrome and components of
metabolic syndrome in the study subjects. Sixty four percent of
patients had MS. Of the components of MS, high blood pressure
(95.8%) was the most common, followed by high fasting glucose
(63.7%) and abdominal obesity (53.8%). MS, metabolic syndrome;
HDL, high-density lipoprotein
Fig. 2 Prevalence of metabolic syndrome across CKD stages. The
prevalence of MS was > 50% even for early stage CKD. The
prevalence of MS was higher in advanced stages of CKD (P < 0.001).
MS, metabolic syndrome
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Fig. 3 Multivariable-adjusted odds ratios of metabolic syndrome according to levels of estimated glomerular filtration rate. An eGFR of 60ml/min/
1.73m2, as a reference value of decreased renal function, was taken as the reference point (OR = 1.00). The adjusted OR of MS was significantly
increased at eGFR levels of < 60ml/min/1.73m2. The model was adjusted for age, sex, eGFR, and overt proteinuria. The solid line represents the
multivariable-adjusted ORs of MS according to levels of eGFR. The dashed lines indicate 95% confidence intervals. eGFR, estimated glomerular filtration
rate; OR, odds ratio; MS, metabolic syndrome
Fig. 4 Serum klotho level according to metabolic syndrome and numbers of metabolic syndrome components. a Serum klotho was significantly
lower in MS patients compared with patients without MS (median [interquartile range]; 521 pg/mL [413, 651] vs. 541 pg/mL [427, 676],
respectively; P = 0.012). b Klotho levels tended to decrease as numbers of MS components increased (P = 0.038). MS, metabolic syndrome
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(Version 9.4, SAS Institute Inc., Cary, NC, USA) were
used for all descriptive and outcome analyses.
Results
Baseline clinical characteristics of subjects according to
the presence of metabolic syndrome
The clinical characteristics of patients at enrollment
are shown in Table 1. Mean age of the 1754 study
subjects was 54.9 ± 12.1 years, and 1110 (63.3%) were
male. Median serum klotho level was 527 pg/mL
(IQR: 418–656 pg/mL). Among them, 1118 (63.7%)
patients exhibited MS. The frequencies of the five MS
component in the study subjects are shown in Fig. 1.
High blood pressure (95.8%) was the most prevalent
component, followed by high fasting glucose (63.7%)
and abdominal obesity (53.8%). Figure 2 presents the
prevalence of MS across CKD stages. The prevalence
of MS was > 50% even for early stage CKD. The
prevalence of MS was higher in advanced stages of
CKD (P < 0.001, P for linear trend < 0.001). As show
in Fig. 3, the adjusted OR (adjusted for age, sex,
eGFR, and overt proteinuria) of MS was significantly
increased at eGFR levels of < 60 ml/min/1.73m2. Sub-
jects were divided into two groups according to the
presence of MS. Patients with MS were older (P < 0.001,
Table 1) and had higher blood pressure (P < 0.001), body
mass index (P < 0.001), and waist circumference (P <
0.001). At enrollment, diabetes mellitus (DM) (P < 0.001),
hypertension (P < 0.001), and preexisting CV disease (P <
0.001) were more prevalent among subjects with MS.
Mean eGFR (P < 0.001) was lower and uric acid (P =
0.025) level was higher in MS patients. Serum klotho was
significantly lower in MS patients compared with patients
without MS (Median [IQR]; 521 pg/mL [413, 651] vs.
541 pg/mL [427, 676], respectively; P = 0.012; Fig. 4a).
In addition, klotho levels tended to decrease as num-
bers of MS components increased (Fig. 4b; P = 0.038).
Clinical characteristics of subjects stratified by serum
klotho level
The clinical characteristics of patients dichotomized
by serum klotho level (lower than median vs. equal to
or higher than median) are shown in Table 2. Age
age, sex, blood pressure, and underlying comorbidities
were similar in these two groups. However, patients
with a lower klotho level had a higher mean uric acid
level (P < 0.001) and a higher C-reactive protein
(CRP) level (P = 0.005). Mean eGFR (P < 0.001) and
hemoglobin (P < 0.001) were lower in the low serum
klotho level group. Serum klotho levels across CKD
stages are shown in Fig. 5. Advanced CKD stages
were associated with lower serum klotho levels (P <
0.001).











Age (years) 55.3 ± 11.9 54.5 ± 12.3 0.152
Sex, male, n (%) 556 (63.4) 554 (63.2) 0.921
SBP (mmHg) 128.9 ± 16.7 128.2 ± 17.2 0.387
DBP (mmHg) 76.3 ± 11.5 76.0 ± 10.9 0.568
BMI (kg/m2) 24.9 ± 3.4 24.6 ± 3.4 0.060
Waist circumference (cm) 88.4 ± 9.8 87.8 ± 9.8 0.203
DM, n (%) 348 (39.7) 352(40.1) 0.845
Hypertension, n (%) 866 (98.7) 853 (97.3) 0.026
Preexisting CV disease, n (%) 144 (16.4) 154 (17.6) 0.525
CAD, n (%) 46 (5.2) 64 (7.3) 0.076
PVD, n (%) 40 (4.6) 36 (4.1) 0.639
Cerebrovascular disease, n (%) 50 (5.7) 60 (6.8) 0.325
HF, n (%) 11 (1.3) 17 (1.9) 0.253
Arrhythmia, n (%) 23 (2.6) 29 (3.3) 0.398
Cause of CKD, n (%) 0.012
GN, n (%) 358 (40.8) 388 (44.2)
Diabetic nephropathy, n (%) 253 (28.8) 238 (27.1)
Hypertension, n (%) 214 (24.4) 175 (20.0)
Others, n (%) 52 (5.9) 73 (8.7)
Laboratory findings
eGFR (mL/min/1.73m2) 44.9 ± 26.0 53.6 ± 30.6 < 0.001
Hemoglobin (g/dL) 12.5 ± 2.0 13.0 ± 2.1 < 0.001
Albumin (g/dL) 4.1 ± 0.4 4.1 ± 0.5 0.953
Uric acid (mg/dL) 7.5 ± 1.9 7.0 ± 1.9 < 0.001
Creatinine (mg/dL) 2.0 ± 1.2 1.8 ± 1.1 < 0.001
hsCRP, median, (IQR) (mg/dL) 0.07 (0.03, 0.18) 0.06 (0.02, 0.15) 0.005
Fasting blood sugar (mg/dL) 110.9 ± 34.9 117.0 ± 49.1 0.003
Total cholesterol (mg/dL) 172.8 ± 39.7 174.0 ± 41.0 0.531
Triglyceride (mg/dL) 168.6 ± 107.0 159.7 ± 98.9 0.072
LDL cholesterol (mg/dL) 95.0 ± 32.3 97.0 ± 33.1 0.205
HDL cholesterol (mg/dL) 47.9 ± 15.9 48.6 ± 15.1 0.356
Overt proteinuriaa, n (%) 475 (61.3) 467 (60.7) 0.821
Klotho, median, (IQR) (pg/mL) 418 (337, 475) 656 (583, 774) < 0.001
Medication, n (%)
ACEi or ARB, n (%) 773 (88.2) 748 (85.5) 0.088
Diuretics, n (%) 342 (39.0) 295 (33.6) 0.058
Statin, n (%) 514 (58.6) 484 (55.2) 0.309
Ca-based P binders, n (%) 88 (10.0) 73 (8.3) 0.396
Metabolic syndrome, n (%) 574 (65.5) 544 (62.0) 0.136
a24-hour urine protein > 500mg/day
MS metabolic syndrome, SBP systolic blood pressure, DBP diastolic blood pressure,
BMI body mass index, DM diabetes mellitus, CV cardiovascular, CAD coronary artery
disease, HF heart failure, PVD peripheral vascular disease, CKD chronic kidney disease,
GN glomerulonephritis, eGFR estimated glomerular filtration rate by CKD-EPI
creatinine equation, hsCRP high sensitivity C-reactive protein, IQR interquartile range,
LDL low-density lipoprotein, HDL high-density lipoprotein, ACEi angiotensin
converting enzyme inhibitor, ARB angiotensin II receptor blocker, Ca calcium,
P phosphorus
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Associations of metabolic syndrome and each metabolic
syndrome component with serum klotho
In the univariate analysis, serum log klotho (OR, 0.40;
95% confidence interval [CI], 0.23–0.72; P = 0.002) and
eGFR (OR, 0.99; 95% CI, 0.98–0.99; P < 0.001) were in-
versely associated with the presence of MS. On the other
hand, age (OR, 1.03; 95% CI, 1.02–1.04; P < 0.001) was
positively associated with MS. Binominal logistic regres-
sion analysis, adjusted for age, sex, eGFR, and overt pro-
teinuria, showed that log klotho was independently
associated with the presence of MS (adjusted OR, 0.44;
95% CI, 0.23–0.82; P = 0.010; model B in Table 3). As
shown in Fig. 6, the adjusted OR of MS was significantly
increased at serum klotho levels of < 518 pg/mL (the
ROC cut-off value). Furthermore, adjusted for age, sex,
eGFR, overt proteinuria, and drug information (ACEi or
ARB, diuretics, statin), log klotho was still independently
associated with the presence of MS (adjusted OR, 0.51;
95% CI, 0.27–0.98; P = 0.045).
ORs of relations between each MS component and
serum klotho are shown in Table 4. Only high blood pres-
sure (adjusted OR, 0.05; 95% CI, 0.01–0.29; P = 0.001) and
hypertriglyceridemia (adjusted OR, 0.48; 95% CI, 0.27–0.87;
P = 0.016) were found to be independently associated with
log klotho. High fasting glucose, abdominal obesity, and
low HDL cholesterol were not significantly associated with
serum klotho.
Subgroup analysis
We further analyzed the relationship between klotho and
MS in several groups. Significant interaction was found in
age group (aged < 50 vs. ≥50 years), suggesting that the as-
sociation between klotho and MS was particularly evident
in subjects aged < 50 years (adjusted OR, 0.18; 95% CI,
0.06–0.56; P = 0.003 vs. adjusted OR, 0.72; 95% CI, 0.33–
1.57; P = 0.412 in aged ≥50 years). Klotho levels tended
to decrease as age increased (Pearson’s correlation coef-
ficient r = − 0.083, P < 0.001), but the value was not large.
Klotho levels were not significantly different in aged < 50
and ≥ 50 years (Median [IQR]; 535 pg/mL [418, 668] vs.
525 pg/mL [418, 655], respectively; P = 0.465). There were
no statistical interactions with sex group (interaction P =
Fig. 5 Serum klotho levels across CKD stages. Advanced CKD stages
were associated with lower serum klotho levels (P < 0.001). CKD,
chronic kidney disease
Table 3 Multivariable logistic regression analysis presenting
associations between log klotho and metabolic syndrome





Log klotho 0.44 (0.25–0.80)d 0.44 (0.23–0.82)d
Age (per year) 1.03 (1.02–1.04)d 1.03 (1.02–1.04)d
Sex (male vs. female) 1.15 (0.94–1.41) 1.13 (0.91–1.40)
eGFR (per mL/min/1.73m2) 1.00 (0.99–1.00)
Overt proteinuriac 1.26 (1.01–1.58)d
OR Odds ratio, CI confidence interval, eGFR estimated glomerular filtration rate
by CKD-EPI creatinine equation
aModel A adjusted for log klotho, age, and sex
bModel B adjusted for covariates in model A plus eGFR, and overt proteinuria
c24-hour urine protein > 500 mg/day
dsignificant association with MS (P < 0.05). P < 0.05 was considered significant
Fig. 6 Multivariable-adjusted odds ratio of metabolic syndrome
according to levels of serum klotho. A serum klotho level of 518 pg/
mL (ROC curve cut-off value) was taken as the reference point (OR =
1.00). The adjusted OR of MS was significantly increased at serum
klotho levels of < 518 pg/mL. The model was adjusted for age, sex,
eGFR, and overt proteinuria. The solid line represents the
multivariable-adjusted ORs of MS according to levels of eGFR. The
dashed lines indicate 95% confidence intervals. Overt proteinuria, 24-
hour urine protein > 500mg/day; ROC, receiver operating
characteristic; eGFR, estimated glomerular filtration rate; OR, odds
ratio; MS, metabolic syndrome
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0.605) and CKD stages (interaction P = 0.425) for the asso-
ciation between klotho and MS.
Discussion
MS, a common clinical phenotype demonstrating as a
combination of metabolic abnormalities including, hyper-
tension, hyperglycemia, hypertriglyceridemia, decreased
high-density lipoprotein cholesterol, and central obesity, is
common in CKD [23]. In the present study, 63.7% of the
1754 CKD patients enrolled exhibited MS. The prevalence
of MS exceeded 50% even in patients with early stage
CKD and its prevalence was higher in advanced CKD
stages. In the univariate analysis, serum klotho was signifi-
cantly lower in patients with MS. After adjusting for vari-
ous factors, such as, age, sex, eGFR, and overt proteinuria,
serum klotho level remained an independent factor associ-
ated with MS in CKD.
In previous studies, genetic variants of Klotho increased
the risk of MS which could be related to their susceptibility
to high fasting glucose, high blood pressure, hypertriglyc-
eridemia, and decreased HDL cholesterol [8, 12]. Klotho
has a role in the regulation of vascular tone through
homeostatic interplay between the renin-angiotensin sys-
tem and nitric oxide [24], which might explain the associ-
ation between klotho and blood pressure. Furthermore, the
Klotho has been shown to be a target gene for PPARγ, a key
transcription factor controlling lipid metabolism and insu-
lin sensitivity [25]. Thus, we speculated these factors might
play major roles in the association of klotho with glucose
and lipid metabolism.
MS is a cluster of risk factors of diabetes and CV disease.
Subjects with CKD present higher incidence of CV disease
and higher CV mortality than the general population
[26, 27]. Novel risk factors such as persistent inflamma-
tion, oxidative stress, and endothelial dysfunction can
be linked to CV disease in CKD patients [28]. Funda-
mental manifestations of MS include insulin resistance
and adipose tissue expansion, and the latter leads to
oxidative stress and chronic inflammation, which aggra-
vate insulin resistance [29–31]. Furthermore, these
pro-inflammatory manifestations of MS might play
roles in the pathogenesis of endothelial dysfunction and
atherosclerosis [32]. Klotho is an anti-aging gene that
extends life span when overexpressed and accelerates
aging when disrupted [6]. Aging which reflects cellular
senescence is closely associated with inflammatory re-
actions, oxidative damage, and endothelial dysfunction
[33–35]. Klotho has also been shown to be an
anti-inflammatory modulator [36, 37], to be closely as-
sociated with oxidative stress [38, 39]. Klotho plays a
role in the protection against endothelial dysfunction
[10]. The kidney is the principal organ responsible for
the production of klotho, and CKD is known to be a
klotho deficient state. Accordingly, the effects of klotho
mentioned above suggest an association between klotho
and MS beyond individual components of MS.
The present study is the first study, to our knowledge,
to report the independent association between serum
klotho level and MS per se especially in CKD patients.
In previous studies, there were not many human studies,
and most of studies were related to the association
between genetic variants of Klotho and individual com-
ponents of MS. In addition, few studies have been per-
formed in patients with CKD. Furthermore, it was the
strength of our study that we included a large-scale
CKD cohort patients and obtained serum klotho level
from a large number of our CKD patients. However, the
study has several limitations that warrant consideration.
First, because it was based on cross-sectional analysis, it
could not demonstrate causality between klotho and
MS. It could not provide detailed mechanistic links be-
tween klotho and MS. We just described the association
between klotho and MS, not the causality. Second,
serum klotho exhibits circadian variations [40]. They
showed that midnight serum klotho level was an ap-
proximately 40% reduction with gradual return to near
baseline values in the early morning hours. Serum
klotho level decreased less than 20% compared with
morning klotho level until 6 p.m. In the present study,
blood samples were not obtained at any fixed time of
the day. However, circadian variation of serum klotho
may have been less in our study because blood sampling
was done before 6 p.m.
Conclusions
Serum klotho levels were found to be independently
and inversely associated with the presence of MS.
Further studies are warranted to elucidate the nature
of the mechanistic link between klotho and MS in
CKD patients.
Table 4 Multivariable logistic regression analysis presenting associations between log klotho and each component of metabolic
syndrome
Variable Adjusted OR (95% CI)
High blood pressure High fasting glucose Abdominal obesity Hypertriglyceridemia Low HDL-cholesterol
Log klotho 0.05 (0.01–0.29) 1.32 (0.70–2.51) 0.68 (0.36–1.28) 0.48 (0.27–0.87) 0.71 (0.38–1.31)
P-value 0.001 0.389 0.235 0.016 0.271
Adjusted for covariates log klotho, age, sex, eGFR, and overt proteinuria
OR Odds ratio, CI confidence interval, HDL high-density lipoprotein, eGFR estimated glomerular filtration rate by CKD-EPI creatinine equation
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